OGC
NBSE

Oak Grove Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Oak Grove Capital’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-959
Closed -$134K – 108
2020
Q4 		$134K Sell
959
-40
-4% -$6.48K 0.04% 67
2020
Q3 		$152K Sell
999
-400
-29% -$65.3K 0.07% 56
2020
Q2 		$246K Buy
+1,399
New +$234K 0.15% 56

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oak Grove Capital's NBSE Position: Q1 2021 in Review

Oak Grove Capital sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2021, closing a stake of 959 shares — an estimated $134K sold.

Oak Grove Capital first reported a position in NBSE in Q2 2020 and held it in 3 quarters. The position peaked at $246K in Q2 2020. 56 funds tracked by Wall St. Rank hold NBSE as of Q1 2021.

  • Oak Grove Capital reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Oak Grove Capital sold 959 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $134K.
  • Oak Grove Capital first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Oak Grove Capital's NeuBase Therapeutics, Inc. Common Stock position peaked at $246K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Oak Grove Capital's 13F filing for Q1 2021, filed 11 May 2021.